ReviewImmunogenetics2019
MHC class II fine tuning by ubiquitination: lesson from MARCHs.
Review in Immunogenetics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Review
- Tilting the Balance: Therapeutic Prospects of CD83 as a Checkpoint Molecule Controlling Resolution of Inflammation.International journal of molecular sciences · 2022Review
- Updating on Roles of HIV Intrinsic Factors: A Review of Their Antiviral Mechanisms and Emerging Functions.Intervirology · 2022Review
- Review
- Biology, evolution, and history of antigen processing and presentation: Immunogenetics special issue 2019.Immunogenetics · 2019Article
- The Membrane-Associated MARCH E3 Ligase Family: Emerging Roles in Immune Regulation.Frontiers in immunology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ubiquitination, a posttranscriptional modification, has been known to contribute to many aspects of cellular event (e.g., protein quality control, signal transduction). In 2007 and 2016, we reported physiological E3 ubiquitin ligases for MHC class II; these are membrane-associated ring-CH-type finger (MARCH)-1 and MARCH-8. Importantly, MARCH-1 and -8 are structurally close to each other, but have different expression profiles. MARCH-1 and -8 are expressed at secondary lymphoid organs and thymic epithelial cells, respectively. These findings suggest contribution of MARCHs to immunological disorders in human; however, its contribution remains to be elucidated. In this review, recent progress on MARCHs will be summarized from molecular and/or immunological point of view and future direction would be discussed.
Indexed as
Identifiers
30377751What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.